PT150
Small moleculeexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2018 (NCT03548714)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorINHIBITOR
NR3C1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07187011 | Phase 2 | Apr 1, 2026 | Department of Defense, Department of Veteran Affairs, Pop Test Oncology LLC |
| NCT06712602 | Phase 1 | Jan 31, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Pop Test Oncology LLC, University of Kentucky |
| NCT04331288 | Phase 1 | May 31, 2020 | Baylor University, Department of Defense, Department of Veteran Affairs, Pharmacotherapies for Alcohol and Substance Abuse Consortium, Pop Test Oncology LLC |
| NCT03548714 | Phase 1 | Jun 1, 2018 | Baylor University, Department of Veteran Affairs, Pharmacotherapies for Alcohol and Substance Abuse Consortium, Pop Test Oncology LLC, University of California, San Diego |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pop Test Oncology LLC | For profit | 4 | 3 | 2 | 2018 |
| Department of Veteran Affairs | Government | 3 | 1 | 2 | 2018 |
| Baylor University | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Department of Defense | Government | 2 | 0 | 2 | 2020 |
| Pharmacotherapies for Alcohol and Substance Abuse Consortium | Academic/Hospital | 2 | 0 | 1 | 2018 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2025 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2025 |
8 organizations
Page 1 / 1